📚 Stock Market Glossary

The GLP-1/GIP/Glucagon Triple Receptor Agonist (exemplified by Eli Lilly's Retatrutide) is a multi-pathway peptide designed to simultaneously engage three major metabolic receptors to treat obesity, diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).

While 1st-gen Wegovy targeted GLP-1 alone and 2nd-gen Zepbound activated GLP-1/GIP dual pathways to achieve –20% weight loss, the 3rd-gen triple agonist adds Glucagon receptor engagement. Glucagon directly oxidizes hepatic lipid stores and accelerates basal energy expenditure, achieving historic weight loss exceeding 24% while drastically clearing liver fat.

• Bariatric Surgery-Level Efficacy: Clinical trials demonstrated a mean 24.2% weight reduction at 48 weeks, rivaling surgical interventions pharmacologically.
• Rapid MASH & Liver Steatosis Resolution: Glucagon activation clears more than 50% of liver fat in over 80% of patients, halting fibrotic progression.
• Elevating Basal Metabolic Rate: Promotes brown adipose tissue thermogenesis, expending calories continuously rather than relying purely on calorie restriction.

Triple agonists expand the total addressable metabolic market across obesity, fatty liver, and cardiovascular risks. Key investment beneficiaries include large-scale peptide CDMOs, auto-injector device manufacturers, and oral formulation innovators. Investors should monitor heart rate elevations and lean muscle mass preservation profiles.